Warning (2) : Undefined array key "profile" [in /var/www/vhosts/marketcap.tools/httpdocs/src/Controller/HomesController.php, line 242]
Warning (2) : Trying to access array offset on value of type null [in /var/www/vhosts/marketcap.tools/httpdocs/src/Controller/HomesController.php, line 242]
Warning (2) : Undefined array key "profile" [in /var/www/vhosts/marketcap.tools/httpdocs/src/Controller/HomesController.php, line 243]
Warning (2) : Trying to access array offset on value of type null [in /var/www/vhosts/marketcap.tools/httpdocs/src/Controller/HomesController.php, line 243]
Warning (512) : Unable to emit headers. Headers sent in file=/var/www/vhosts/marketcap.tools/httpdocs/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php line=36 [in /var/www/vhosts/marketcap.tools/httpdocs/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 71]
Warning (2) : Cannot modify header information - headers already sent by (output started at /var/www/vhosts/marketcap.tools/httpdocs/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php:36) [in /var/www/vhosts/marketcap.tools/httpdocs/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 164]
Warning (2) : Cannot modify header information - headers already sent by (output started at /var/www/vhosts/marketcap.tools/httpdocs/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php:36) [in /var/www/vhosts/marketcap.tools/httpdocs/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 197]
Warning (2) : Cannot modify header information - headers already sent by (output started at /var/www/vhosts/marketcap.tools/httpdocs/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php:36) [in /var/www/vhosts/marketcap.tools/httpdocs/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 236]
Mereo BioPharma Group plc - Market capitalization
Mereo BioPharma Group plc
MREO

$528.55 M
Marketcap
$3.58
Share price
Country
N/A
Change (1 day)
N/A
Year High
N/A
Year Low
Categories

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.

marketcap